Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Venous thromboembolism during pregnancy

7,164 views

Published on

Venous thromboembolism during pregnancy

  • Be the first to comment

Venous thromboembolism during pregnancy

  1. 1. ` VENOUS THROMBOEMBOLISM DURING PREGNANCY 1A-MOWAFY 2013 VTE = Venous thromboembolism Includes; Deep venous thrombosis DVT, Pulmonary embolism PE INCIDENCE :  2-3 in 1000 pregnancies  DVT 80% PE 20%  2/3 of DVT are antepartum  Caesarean section increases the risk 3-5 fold than vaginal delivery PATHOGENESIS Virchow’s triade = 1. Circulatory stasis 2. Vascular damage 3. Increased blood co-agulation AETIOLOGY Risk factors: 1. Pregnancy itself is a risk factor 2. Previous VTE in patient on hormonal contraception 3. Previous VTE during pregnancy ( risk is 12 % ) 4. Rheumatic heart disease and patients with heart prosthesis 5. Thrombophilias (congenital and acquired?!) 6. Age ˃ 35 years old 7. Obesity ; BMI ˃ 30 8. Multiparity ; parity ˃ 4 9. Recurrent miscarriage 10. Bed rest and physical immobility 11. Hyperemesis gravidarum 12. Shock and dehydration 13. Infections Venous thromboembolism during pregnancy Venous thromboembolism during pregnancy
  2. 2. ` VENOUS THROMBOEMBOLISM DURING PREGNANCY 2A-MOWAFY 2013 14. Pregnancy-induced hypertension 15. Excessive blood loss 16. Prolonged labour 17. Instrumental delivery 18. Cesarean section 19. Pelvic surgery in peri-partum period 20. Sickle cell anemia 21. Gross varicose veins 22. Fetal demise with remaining viable fetus 23. Intra-uterine gross restriction IUGR Q: What is thrombophilia? It is abnormalities in the blood co-agulation that is increases the risk of thrombosis; (congenital, Acquired?)
  3. 3. ` VENOUS THROMBOEMBOLISM DURING PREGNANCY 3A-MOWAFY 2013 RISKY GROUPS AND THEIR MANAGEMENT: Very high risk Criteria  Previous VTE with thrombophilia  Long term warfarin therapy Antepartum  High prophylactic dose or therapeutic dose of LMWH Postpartum  LMWH for 5 days + Warfarin High risk Criteria  Previous recurrent VTE  VTE once with thrombophilia  VTE once with positive family history  Diagnosed important thrombophilia  Valvular mechanical prosthesis Antepartum  prophylactic dose LMWH Postpartum  LMWH for 5 days + Warfarin for 6 weeks Moderate risk Criteria  Single provoked VTE without thrombophilia  Thrombophilia + Anti-thrombin III deficiency  Mitral stenosis Antepartum  Antenatal aspirin Postpartum  LMWH for 5 days + Warfarin for 6 weeks Low risk Criteria Two or more of the following :  Obesity  Age ˃ 35  Parity ˃ 4  Gross varicose veins  Recurrent hypertensive disorders Antepartum  Antenatal aspirin Postpartum  Warfarin for 6 weeks
  4. 4. ` VENOUS THROMBOEMBOLISM DURING PREGNANCY 4A-MOWAFY 2013 ANTI-COAGULANT DRUGS: Heparin Types I. Unfractionated heparin → UFH “Cal-heparin” II. Low molecular weight heparin → LMWH “Clexan” Onset Within 10 minutes Half-life 6 hours Doses I. Unfractionated heparin  Normal body weight → 5000 IU/day  Body weight ˂ 50 kg → 2500 IU/day  Body weight ˃ 90 kg → 5000 IU/12 h  High prophylactic dose→ 100 IU/kg/12h II. Low molecular weight heparin  Normal body weight → 40 mg/day  Body weight ˂ 50 kg → 20 mg /day  Body weight ˃ 90 kg → 40 mg / 12h  High prophylactic dose→ I mg/kg/12h Monitoring 1. Activated partial thromboplastin aPPT twice weekly 2. Plattlets concentration monthly 3. Bone mineral density every 3 months Advantages 1. No effect on the fetus ( does not cross placental blood barrier ) 2. Not secreted on milk ( no effect on lactation ) N.B : advantages of LMWH over UFH o Fewer side effect o Prolonged half-life o Greater inhibitory effect on factor X o Prophylactic dose once daily o No need for continuous laboratory monitoring Drawbacks  Increase bleeding tendency  Osteoporosis ( improved by adding calcium , hence name “ Cal-heparin “  Fat necrosis at site of injection  Alopecia Anti-dot Protamine sulphate 1mg/100IU
  5. 5. ` VENOUS THROMBOEMBOLISM DURING PREGNANCY 5A-MOWAFY 2013 Oral anti-coagulant drugs Types I. Coumarine → Warfarin sodium “Marevan” II. Indandione → phenoidione “Dindevan” Onset Full effect after 5 days Half-life  Warfarin → 44 hours  Phenoidione → 5 hours Doses 2 to 5 mg/day Monitoring 1. INR = “ international randomized ratio “→ should be 2 to 3 2. PT = “ prothrombine time “→ 30–50 % of normal control Advantages Oral route , potent and long acting Drawbacks  Maternal : 1. Skin: allergy, fever, rash, urticarial and dermatitis 2. Blood: agranulocytosis 3. Liver: liver disturbances; jaundice 4. Renal: renal disturbances; hematuria 5. Over dose → bleeding tendency  Fetal : 1. Warfarin embryopathy; nasal hypoplasia, depression of nasal bone, mental retardation, optic atrophy, skeletal defect ‘ bone splitting’ 2. Can cross placental-blood barrier; bleeding tendency and increases the risks of intracranial hemorrhage and accidental hemorrhage  Drug interactions : 1. drugs increases the effect : salicylates, quinine, steroids 2. drugs decreases the effect : hepatic enzyme inducers Anti-dot  Vitamin K IM. , SC.  For rapid effect : 1. Fresh blood , fresh frozen plasma 2. Vitamin K to the mother and baby PROTOCOLS FOR ANTI-COAGULATION DURING PREGNANCY Frist trimester → only heparin for fear of warfarin embryopathy Second trimester → warfarin starting from 13 weeks Continue till:  33 weeks if risk of preterm laobour exist  36 weeks if no risk of preterm labour However, oral anti-coagulants are not absolutely safe as delayed warfarin embryopathy is recorded Late in pregnancy: at 33 – 36 weeks → shift to heparin again Postpartum: Vitamin K to the mother and baby and readjust the dose

×